Atrovent and Yervoy drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Atrovent (ipratropium bromide) and Yervoy (ipilimumab). Common drug interactions include malignant neoplasm progression among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Atrovent and Yervoy. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.

What is Atrovent?

Atrovent has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 33,210 Atrovent users. Check the latest studies of Atrovent.

What is Yervoy?

Yervoy has active ingredients of ipilimumab. eHealthMe is studying from 26,662 Yervoy users. Check the latest studies of Yervoy.

On Jul, 31, 2026

24 people who take Atrovent and Yervoy together, and have interactions are studied.

What are the common drug interactions of Atrovent and Yervoy, by gender? *:

female:

Malignant neoplasm progression (cancer tumour came back)
Asthenia (weakness)
Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
Colitis (inflammation of colon)
Hypophagia (reduced food intake)
Pulmonary embolism (blockage of the main artery of the lung)
Injection site inflammation
Blood urea increased
Death
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)

male:

Death
Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
Septic shock (shock due to blood infection)
Ischaemic cardiomyopathy (weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease)
Pneumonia
Pneumonitis (inflammation of the walls of the alveoli in the lungs)
Thermal burn (burn by heat)
Anaemia of malignant disease
Fatigue (feeling of tiredness)
Infective exacerbation of chronic obstructive airways disease (severe infective lung disease with chronic obstructive airways disease)

What are the common drug interactions of Atrovent and Yervoy, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

Death
Pyrexia (fever)

40-49:

Lower respiratory tract infection
Malignant neoplasm progression (cancer tumour came back)
Pneumonitis (inflammation of the walls of the alveoli in the lungs)

50-59:

n/a

60+:

Pulmonary embolism (blockage of the main artery of the lung)
Asthenia (weakness)
Lethargy (tiredness)
Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
Neutropenia (an abnormally low number of neutrophils)
Respiratory failure (inadequate gas exchange by the respiratory system)
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)
Septic shock (shock due to blood infection)
Injection site inflammation
Ischaemic cardiomyopathy (weakness in the muscle of the heart due to inadequate oxygen delivery to the myocardium with coronary artery disease)

What are the existing conditions these people have? *

Lung Cancer - Non-Small Cell (lung cancer): 8 people, 33.33%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 6 people, 25.00%
Lung Neoplasm Malignant (cancer tumour of lung): 5 people, 20.83%
High Blood Pressure: 4 people, 16.67%
Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down): 3 people, 12.50%
Respiratory Distress (difficulty in breathing): 3 people, 12.50%
Pain: 3 people, 12.50%
High Blood Cholesterol: 3 people, 12.50%
Dyspnea (difficult or laboured breathing): 3 people, 12.50%
Diarrhea: 3 people, 12.50%

* Approximation only. Some reports may have incomplete information.

Do you take Atrovent and Yervoy?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously